J, M., L, B., X, Z., F, E., M, F., C, R., . . . L, R. (2026). Significant burden of low-grade infections in patients treated with T-cell-engaging therapies for multiple myeloma. Blood advances, 10(7), 2244. https://doi.org/10.1182/bloodadvances.2025017889
Chicago Style (17th ed.) CitationJ, Mersi, et al. "Significant Burden of Low-grade Infections in Patients Treated with T-cell-engaging Therapies for Multiple Myeloma." Blood Advances 10, no. 7 (2026): 2244. https://doi.org/10.1182/bloodadvances.2025017889.
MLA (9th ed.) CitationJ, Mersi, et al. "Significant Burden of Low-grade Infections in Patients Treated with T-cell-engaging Therapies for Multiple Myeloma." Blood Advances, vol. 10, no. 7, 2026, p. 2244, https://doi.org/10.1182/bloodadvances.2025017889.
Warning: These citations may not always be 100% accurate.
